Harm reduction product distribution in British Columbia

Canadian Journal of Public Health

Volumn 99, Issue 6, 2008, Pages 446-450

  Harvard, Stephanie S ^a,b   Hill, Warren D ^a   Buxton, Jane A ^a,b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

British Columbia; Harm reduction; Intravenous; Needle exchange programs; Substance abuse

Indexed keywords

EID: 58149496610     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03403773     Document Type: Article

References (21)

1. BC Ministry of Health. Harm reduction: A British Columbia Community Guide. Vancouver, BC: BC Ministry of Health, 2004. Available online at: http://www.health.gov.bc.ca/prevent/pdf/hrcommunityguide.pdf (Accessed July 24, 2007).
2. BC Centre for Disease Control. BC Harm Reduction Supply Services Policy and Guidelines. Vancouver, BC: BC Centre for Disease Control, 2004. Available online at: http://www.bccdc.org/download.php?item=1040 (Accessed July 24, 2007).
3. World Health Organization. Biregional strategy for harm reduction: HIV and injecting drug use. Geneva, Switzerland: World Health Organization, 2005. Available online at: http://www.wpro.who.int/publications/PUB_92 90611952.htm (Accessed August 8, 2007).
4. World Health Organization. Evidence for Action: Effectiveness of Sterile Needle and Syringe Programming. Geneva: World Health Organization, 2004. Available online at: http://www.who.int/hiv/pub/prev_care/en/ effectivenesssterileneedle.pdf (Accessed August 8, 2007).
5. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102:1454-62.
6. Zou S, Forrester L, Giulivi A. Hepatitis C update. Can J Public Health 2003;94(2):127-29.
7. BC Centre for Disease Control. Enhanced Hepatitis Strain Surveillance System (EHSSS) Review, Vancouver, BC: BC Centre for Disease Control, 2005.
8. Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CAMJ 2001;165(7):889-95.
9. Wood E, Kerr T, Stoltz J, Qui Z, Zhang R, Montaner JS, et al. Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility. Public Health 2005;119(12):1111-15.
10. Fischer B, Powis J, Firestone Cruz M, Rudzinski K. Hepatitis C virus transmission among oral crack users: Viral detection on crack paraphernalia. Eur J Gastroenterology Hepatology 2008;20:29-32.
11. Tortu S, McMahon J, Pouget E, Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst Use Misuse 2004;39:211-24.
12. Remis RS, Bruneau J, Hankins CA. Enough sterile syringes to prevent HIV transmission among injection drug users in Montreal? J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S57-S59.
13. Canadian Community Epidemiology Network on Drug Use. Vancouver Drug Use Epidemiology. Vancouver, BC: Canadian Community Epidemiology Network on Drug Use, 2005. Available online at: http://www.city.vancouver.bc.ca/ fourpillars//pdf/report_vancouver_2005.pdf (Accessed July 5, 2007).
14. Canadian Centre on Substance Abuse. Canadian Addiction Survey 2004. Ottawa, ON: Canadian Centre on Substance Abuse, 2004.
15. Vancouver Coastal Health. Injection drug use in the DTES. Vancouver, BC: Vancouver Coastal Health, 2003. Available online at: http://www.vch.ca/ sis/docs/SIS_Info_Sheet.pdf (Accessed July 5, 2007).
16. Vancouver Coastal Health. Saving Lives: Vancouver's Supervised Injection Site. 2006. Available online at: http://www.vch.ca/sis/docs/ insite_brochure.pdf (Accessed January 15, 2008).
17. Public Health Agency of Canada. I-Track: Enhanced surveillance of risk behaviours among injecting drug users in Canada. Ottawa: Public Health Agency of Canada, 2006. Available online at: http://www.phac-aspc.gc.ca/ i-track/sr-re-1/pdf/itrack06_e.pdf (Accessed January 15, 2008).
18. Prithwish D, Cox J, Boivin JF, Platt RW, Jolly AM. Rethinking approaches to risk reduction for injection drug users: Differences in drug type affect risk for HIV and hepatitis C virus infection through drug-injecting networks. J Acquir Immune Defic Syndr 2007;46(3):355-61.
19. Aceijas C, Hickman M, Donoghoe MC, Burrows D, Stuikyte R. Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. Addiction 2007;102:1244-50.
20. Hickman M, Higgins V, Hope V, Bellis M, Tilling K, Walker A, Henry J. Injecting drug use in Brighton, Liverpool, and London: Best estimates of prevalence and coverage of public health indicators. J Epidemiol Community Health 2004;58:766-71.
21. Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007;91(2-3):228-35. Epub 2007 Jul 31.